Targeting proprotein convertase subtilisin/kexin type 9(PCSK9):from bench to bedside  

作　　者：Xuhui Bao Yongjun Liang Hanman Chang Tianji Cai Baijie Feng Konstantin Gordon Yuekun Zhu Hailian Shi Yundong He Liyi Xie 

机构地区：[1]Institute of Therapeutic Cancer Vaccines,Fudan University Pudong Medical Center,Shanghai,China [2]Shanghai Key Laboratory of Regulatory Biology,School of Life Sciences,East China Normal University,Shanghai,China [3]Department of Oncology,Fudan University Pudong Medical Center,Shanghai,China [4]Center for Clinical Research,Fudan University Pudong Medical Center,Shanghai,China [5]Clinical Research Center for Cell-based Immunotherapy,Fudan University,Shanghai,China [6]Department of Pathology,Duke University Medical Center,Durham,NC,USA [7]Center for Medical Research and Innovation,Fudan University Pudong Medical Center,Shanghai,China [8]Institute for Food Safety and Health,Illinois Institute of Technology,Chicago,IL,USA [9]Department of Sociology,University of Macao,Taipa,Macao,China [10]Medical Institute,Peoples’Friendship University of Russia,Moscow,Russia [11]A.Tsyb Medical Radiological Research Center,Obninsk,Russia [12]Department of Colorectal Surgery,The First Affiliated Hospital of Harbin Medical University,Harbin,Heilongjiang,China [13]Shanghai Key Laboratory of Compound Chinese Medicines,Institute of Chinese Materia Medica,Shanghai University of Traditional Chinese Medicine,Zhangjiang Hi-tech Park,Shanghai,China [14]Department of Radiation Oncology,Fudan University Shanghai Cancer Center,Shanghai,China [15]Department of Oncology,Shanghai Medical College,Fudan University,Shanghai,China

出　　处：《Signal Transduction and Targeted Therapy》2024年第2期509-557,共49页信号转导与靶向治疗（英文）

基　　金：supported by the National Natural Science Foundation of China(No.82272817,to X.B.);Shanghai Pujiang Program(No.22PJ1412400,to X.B.,and No.22PJ1402700,to Y.H.);Science and Technology Development Fund of Shanghai Pudong New Area(No.PKJ2022-Y50,to X.B.).

摘　　要：Proprotein convertase subtilisin/kexin type 9(PCSK9)has evolved as a pivotal enzyme in lipid metabolism and a revolutionary therapeutic target for hypercholesterolemia and its related cardiovascular diseases(CVD).This comprehensive review delineates the intricate roles and wide-ranging implications of PCSK9,extending beyond CVD to emphasize its significance in diverse physiological and pathological states,including liver diseases,infectious diseases,autoimmune disorders,and notably,cancer.Our exploration offers insights into the interaction between PCSK9 and low-density lipoprotein receptors(LDLRs),elucidating its substantial impact on cholesterol homeostasis and cardiovascular health.It also details the evolution of PCSK9-targeted therapies,translating foundational bench discoveries into bedside applications for optimized patient care.The advent and clinical approval of innovative PCSK9 inhibitory therapies(PCSK9-iTs),including three monoclonal antibodies(Evolocumab,Alirocumab,and Tafolecimab)and one small interfering RNA(siRNA,Inclisiran),have marked a significant breakthrough in cardiovascular medicine.These therapies have demonstrated unparalleled efficacy in mitigating hypercholesterolemia,reducing cardiovascular risks,and have showcased profound value in clinical applications,offering novel therapeutic avenues and a promising future in personalized medicine for cardiovascular disorders.Furthermore,emerging research,inclusive of our findings,unveils PCSK9’s potential role as a pivotal indicator for cancer prognosis and its prospective application as a transformative target for cancer treatment.This review also highlights PCSK9’s aberrant expression in various cancer forms,its association with cancer prognosis,and its crucial roles in carcinogenesis and cancer immunity.In conclusion,this synthesized review integrates existing knowledge and novel insights on PCSK9,providing a holistic perspective on its transformative impact in reshaping therapeutic paradigms across various disorders.It emphasizes the clin

关 键 词：PCSK9 METABOLISM CONVERT 

分 类 号：R54[医药卫生—心血管疾病]